Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

REPLIMUNE GROUP, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

REPLIMUNE GROUP, INC. (REPL) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$69.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-14

  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$69.77M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$73.22M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$70.93M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$83.10M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2026 was -$313.94M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$247.30M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$215.79M.
  • REPLIMUNE GROUP, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$174.28M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed
2026-06-30-$69.77M
10-Q · filed 2026-08-14
-$142.98M
derived: sum of 2 quarters · filed 2026-08-14
-$213.91M
derived: sum of 3 quarters · filed 2026-08-14
-$297.01M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$73.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
-$144.15M
derived: sum of 2 quarters · filed 2026-06-29
-$227.25M
derived: sum of 3 quarters · filed 2026-06-29
-$313.94M
10-K · filed 2026-06-29
2025-12-31-$70.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03
-$154.03M
derived: sum of 2 quarters · filed 2026-02-03
-$240.72M
10-Q · filed 2026-02-03
-$314.85M
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30-$83.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06
-$169.79M
10-Q · filed 2025-11-06
-$243.92M
derived: sum of 3 quarters · filed 2026-08-14
-$310.26M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$86.69M
10-Q · filed 2026-08-14
-$160.82M
derived: sum of 2 quarters · filed 2026-08-14
-$227.16M
derived: sum of 3 quarters · filed 2026-08-14
-$280.22M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$74.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
-$140.47M
derived: sum of 2 quarters · filed 2026-06-29
-$193.53M
derived: sum of 3 quarters · filed 2026-06-29
-$247.30M
10-K · filed 2026-06-29
2024-12-31-$66.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03
-$119.39M
derived: sum of 2 quarters · filed 2026-02-03
-$173.17M
10-Q · filed 2026-02-03
-$228.24M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30-$53.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06
-$106.83M
10-Q · filed 2025-11-06
-$161.90M
derived: sum of 3 quarters · filed 2025-11-06
-$213.02M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$53.77M
10-Q · filed 2025-08-07
-$108.85M
derived: sum of 2 quarters · filed 2025-08-07
-$159.97M
derived: sum of 3 quarters · filed 2025-08-07
-$220.01M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$55.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22
-$106.19M
derived: sum of 2 quarters · filed 2025-05-22
-$166.24M
derived: sum of 3 quarters · filed 2025-05-22
-$215.79M
10-K · filed 2025-05-22
2023-12-31-$51.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12
-$111.16M
derived: sum of 2 quarters · filed 2025-02-12
-$160.72M
10-Q · filed 2025-02-12
-$209.96M
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30-$60.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12
-$109.60M
10-Q · filed 2024-11-12
-$158.84M
derived: sum of 3 quarters · filed 2024-11-12
-$198.53M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$49.55M
10-Q · filed 2024-08-08
-$98.79M
derived: sum of 2 quarters · filed 2024-08-08
-$138.48M
derived: sum of 3 quarters · filed 2024-08-08
-$181.59M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$49.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16
-$88.93M
derived: sum of 2 quarters · filed 2024-05-16
-$132.03M
derived: sum of 3 quarters · filed 2024-05-16
-$174.28M
10-K · filed 2024-05-16
2022-12-31-$39.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08
-$82.79M
derived: sum of 2 quarters · filed 2024-02-08
-$125.05M
10-Q · filed 2024-02-08
-$156.74M
derived: sum of 4 quarters · filed 2024-02-08
2022-09-30-$43.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07
-$85.36M
10-Q · filed 2023-11-07
-$117.05M
derived: sum of 3 quarters · filed 2023-11-07
-$146.72M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$42.25M
10-Q · filed 2023-08-03
-$73.95M
derived: sum of 2 quarters · filed 2023-08-03
-$103.62M
derived: sum of 3 quarters · filed 2023-08-03
-$132.98M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$31.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18
-$61.37M
derived: sum of 2 quarters · filed 2023-05-18
-$90.72M
derived: sum of 3 quarters · filed 2023-05-18
-$118.04M
10-K · filed 2023-05-18
2021-12-31-$29.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09
-$59.03M
derived: sum of 2 quarters · filed 2023-02-09
-$86.34M
10-Q · filed 2023-02-09
-$107.84M
derived: sum of 4 quarters · filed 2023-02-09
2021-09-30-$29.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03
-$56.67M
10-Q · filed 2022-11-03
-$78.17M
derived: sum of 3 quarters · filed 2022-11-03
-$99.95M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30-$27.31M
10-Q · filed 2022-08-04
-$48.81M
derived: sum of 2 quarters · filed 2022-08-04
-$70.59M
derived: sum of 3 quarters · filed 2022-08-04
-$90.69M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$21.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19
-$43.28M
derived: sum of 2 quarters · filed 2022-05-19
-$63.38M
derived: sum of 3 quarters · filed 2022-05-19
-$80.87M
10-K · filed 2022-05-19
2020-12-31-$21.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03
-$41.88M
derived: sum of 2 quarters · filed 2022-02-03
-$59.37M
10-Q · filed 2022-02-03
-$75.16M
derived: sum of 4 quarters · filed 2022-02-03
2020-09-30-$20.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-04
-$37.59M
10-Q · filed 2021-11-04
-$53.38M
derived: sum of 3 quarters · filed 2021-11-04
-$69.57M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$17.49M
10-Q · filed 2021-08-06
-$33.28M
derived: sum of 2 quarters · filed 2021-08-06
-$49.47M
derived: sum of 3 quarters · filed 2021-08-06
-$60.61M
derived: sum of 4 quarters · filed 2021-08-06
2020-03-31-$15.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20
-$31.98M
derived: sum of 2 quarters · filed 2021-05-20
-$43.12M
derived: sum of 3 quarters · filed 2021-05-20
-$52.63M
10-K · filed 2021-05-20
2019-12-31-$16.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-04
-$27.33M
derived: sum of 2 quarters · filed 2021-02-04
-$36.84M
10-Q · filed 2021-02-04
-$43.49M
derived: sum of 4 quarters · filed 2021-02-04
2019-09-30-$11.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-05
-$20.65M
10-Q · filed 2020-11-05
-$27.30M
derived: sum of 3 quarters · filed 2020-11-05
-$34.98M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$9.51M
10-Q · filed 2020-08-07
-$16.16M
derived: sum of 2 quarters · filed 2020-08-07
-$23.84M
derived: sum of 3 quarters · filed 2020-08-07
-$30.30M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31-$6.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
-$14.33M
derived: sum of 2 quarters · filed 2020-06-03
-$20.79M
derived: sum of 3 quarters · filed 2020-06-03
-$30.83M
10-K · filed 2020-06-03
$30.83M
10-K · filed 2019-06-28
2018-12-31-$7.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13
-$14.13M
derived: sum of 2 quarters · filed 2020-02-13
-$24.18M
10-Q · filed 2020-02-13
-$31.03M
derived: sum of 4 quarters · filed 2020-06-03
2018-09-30-$6.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12
-$16.50M
10-Q · filed 2019-11-12
-$23.35M
derived: sum of 3 quarters · filed 2020-06-03
-$28.00M
derived: sum of 4 quarters · filed 2020-06-03
2018-06-30-$10.04M
10-Q · filed 2019-08-14
-$16.89M
derived: sum of 2 quarters · filed 2020-06-03
-$21.53M
derived: sum of 3 quarters · filed 2020-06-03
-$26.19M
derived: sum of 4 quarters · filed 2020-06-03
2018-03-31-$6.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
-$11.49M
derived: sum of 2 quarters · filed 2020-06-03
-$16.15M
derived: sum of 3 quarters · filed 2020-06-03
-$19.70M
10-K · filed 2020-06-03
$19.70M
10-K · filed 2019-06-28
2017-12-31-$4.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14
-$9.30M
derived: sum of 2 quarters · filed 2019-02-14
-$12.85M
10-Q · filed 2019-02-14
2017-09-30-$4.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14
-$8.21M
10-Q · filed 2018-11-14
2017-06-30-$3.55M
10-Q · filed 2018-08-30
2017-03-31$7.70M
10-K · filed 2019-06-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B